Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2018
At a glance
- Drugs Eltrombopag (Primary)
- Indications Immune thrombocytopenic purpura
- Focus Therapeutic Use
- Acronyms ESTIT
- 25 Feb 2018 New Source identified and integrated ( EudraCT2015-001327-23: European Clinical Trials Database ).
- 23 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2018.
- 17 Feb 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.